Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its ...

BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX), its partner for the Comirnaty COVID-19 vaccine, made legal submissions to London's Court of Appeal on Thursday seeking to overturn a prior court ruling ...

Pfizer Inc. (NYSE: PFE), a global pharmaceutical giant with a market capitalization of $138.21 billion, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...

Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents, in the latest round of a long ...

Pfizer’s pipeline remains a crucial component of its long-term growth strategy. The company has made significant strides in key therapeutic areas, particularly in oncology and obesity treatments.

Pfizer, BioNTech challenge Moderna’s COVID vaccine patent win in U.K. Jul. 10, 2025 8:08 AM ET Pfizer Inc. (PFE) Stock, MRNA Stock, BNTX Stock By: Dulan Lokuwithana, SA News Editor 1 Comment ...

Pfizer Inc. s fourth-quarter profit fell by half as worsening generic competition and unfavorable currency rates reduced sales, and higher research spending and legal costs also hurt the bottom line.